Pre-made Elipovimab benchmark antibody ( Whole mAb, anti-HIV-1 gp120 therapeutic antibody) for drug discovery and mechanism of action (MOA) research

Cat No.: GMP-Bios-ab-171

Pre-Made Elipovimab biosimilar, Whole Mab: Anti-HIV-1 gp120 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Elipovimab (formerly known as GS-9722) is a first in class of effector-enhanced broadly neutralizing HIV-1 antibodies for the targeted elimination of HIV infected cells and is as of 2020 in phase 1b clinical testing, designed with the goal of reducing or eliminating the HIV reservoir in patients.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No. Package List Price(In USD) Discount off Discount Price
GMP-Bios-ab-171-1mg 1mg 3090 30% 2163

Size: 1mg | 10mg | 100mg


Products Name (INN Index) Pre-Made Elipovimab biosimilar, Whole Mab: Anti-HIV-1 gp120 therapeutic antibody
INN Name Elipovimab
TargetHIV-1 gp120
FormatWhole mAb
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCLambda
Highest_Clin_Trial (Jan '20)Phase-I
Est. StatusActive
100% SI StructureNone
99% SI StructureNone
95-98% SI Structure4fq1:HL/4jy4:BA/4fqc:HL
Year Proposed2018
Year Recommended2019
CompaniesGilead Sciences
Conditions Approvedna
Conditions ActiveHIV infections
Conditions Discontinuedna
Development Techna